Ponvory

Ponvory · pharmadog

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 16, 2029

~3.4 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (50)

Oct 10, 2042method-of-use (U-3891)US 11951097
Oct 10, 2042method-of-use (U-3891)US 11951097
Oct 10, 2042method-of-use (U-3891)US 11951097
Oct 10, 2042method-of-use (U-3891)US 11951097
Oct 10, 2042method-of-use (U-3891)US 11951097
Oct 10, 2042method-of-use (U-3891)US 11951097
Oct 10, 2042method-of-use (U-3891)US 11951097
Oct 10, 2042method-of-use (U-3891)US 11951097
Oct 10, 2042method-of-use (U-3891)US 11951097
Oct 10, 2042method-of-use (U-3891)US 11951097
Dec 10, 2035method-of-use (U-3103)US 10220023
Dec 10, 2035method-of-use (U-3103)US 10220023
Dec 10, 2035method-of-use (U-3103)US 10220023
Dec 10, 2035method-of-use (U-3103)US 10220023
Dec 10, 2035method-of-use (U-3103)US 10220023
Dec 10, 2035method-of-use (U-3103)US 10220023
Dec 10, 2035method-of-use (U-3103)US 10220023
Dec 10, 2035method-of-use (U-3103)US 10220023
Dec 10, 2035method-of-use (U-3103)US 10220023
Dec 10, 2035method-of-use (U-3103)US 10220023
Dec 10, 2035method-of-use (U-3103)US 12336980
Dec 10, 2035method-of-use (U-3103)US 12336980
Dec 10, 2035method-of-use (U-3103)US 12336980
Dec 10, 2035method-of-use (U-3103)US 12336980
Dec 10, 2035method-of-use (U-3103)US 12336980
Dec 10, 2035method-of-use (U-3103)US 12336980
Dec 10, 2035method-of-use (U-3103)US 12336980
Dec 10, 2035method-of-use (U-3103)US 12336980
Dec 10, 2035method-of-use (U-3103)US 12336980
Dec 10, 2035method-of-use (U-3103)US 12336980
May 6, 2032compositionUS 9062014
May 6, 2032compositionUS 9062014
May 6, 2032compositionUS 9062014
May 6, 2032compositionUS 9062014
May 6, 2032compositionUS 9062014
May 6, 2032compositionUS 9062014
May 6, 2032compositionUS 9062014
May 6, 2032compositionUS 9062014
May 6, 2032compositionUS 9062014
May 6, 2032compositionUS 9062014
Nov 16, 2029compositionUS RE437283.4y
Nov 16, 2029compositionUS RE437283.4y
Nov 16, 2029compositionUS RE437283.4y
Nov 16, 2029compositionUS RE437283.4y
Nov 16, 2029compositionUS RE437283.4y
Nov 16, 2029compositionUS RE437283.4y
Nov 16, 2029compositionUS RE437283.4y
Nov 16, 2029compositionUS RE437283.4y
Nov 16, 2029compositionUS RE437283.4y
Nov 16, 2029compositionUS RE437283.4y

FDA exclusivities (10)

Mar 18, 2026NCENew Chemical Entity (5y)
Mar 18, 2026NCENew Chemical Entity (5y)
Mar 18, 2026NCENew Chemical Entity (5y)
Mar 18, 2026NCENew Chemical Entity (5y)
Mar 18, 2026NCENew Chemical Entity (5y)
Mar 18, 2026NCENew Chemical Entity (5y)
Mar 18, 2026NCENew Chemical Entity (5y)
Mar 18, 2026

ponesimod

indications

targets

all catalysts(0)

News(0)

Report a data issue

comments(0)

Patent cliff

patents (50)

FDA exclusivities (10)

Trials studying ponesimod